Antibe Therapeutics Inc. (TSE:ATE) Director John Lawrence Wallace Sells 21,500 Shares
Antibe Therapeutics Inc. (TSE:ATE) Director John Lawrence Wallace Sells 21,500 Shares
Antibe Therapeutics Inc. (TSE:ATE – Get Rating) Director John Lawrence Wallace sold 21,500 shares of Antibe Therapeutics stock in a transaction on Thursday, July 7th. The stock was sold at an average price of C$0.62, for a total transaction of C$13,330.00. Following the sale, the director now directly owns 1,899,576 shares of the company's stock, valued at C$1,177,737.12.
安提貝治療公司(多倫多證券交易所代碼:ATE-GET評級)董事約翰·勞倫斯·華萊士在7月7日星期四的一筆交易中出售了21,500股安提伯治療公司的股票。該股以0.62加元的平均價格出售,總成交金額為13,330.00加元。交易完成後,董事現在直接持有該公司1,899,576股股票,價值1,177,737.12加元。
TSE ATE opened at C$0.62 on Wednesday. Antibe Therapeutics Inc. has a 52-week low of C$0.59 and a 52-week high of C$3.65. The company has a debt-to-equity ratio of 0.29, a quick ratio of 11.92 and a current ratio of 13.07. The company has a market capitalization of C$31.86 million and a P/E ratio of -1.16. The company has a fifty day moving average of C$0.66 and a 200-day moving average of C$0.70.
週三,Tse ATE開盤報0.62加元。安提貝治療公司的股價跌至0.59加元的52周低點和3.65加元的52周高點。該公司的負債權益比率為0.29,速動比率為11.92,流動比率為13.07。該公司市值為3,186萬加元,市盈率為-1.16。該公司的50日移動均線切入位在0.66加元,200日移動均線切入位在0.70加元。
Antibe Therapeutics Company Profile (Get Rating)
安提貝治療公司簡介(獲取評級)
Read More
閲讀更多內容
- Should These Two Airlines Be In Your Portfolio?
- Old Dominion Freight Line (ODFL): This Dividend Growth Stock Deserves Your Attention
- Is There a Reasonable Price to Buy Stitch Fix Stock?
- 3 Smid Caps Under $20 Set to Recover
- Continuining to Assess Tesla's Future As The EV Market Becomes Increasingly Competitive
- 這兩家航空公司應該在你的投資組合中嗎?
- Old Dominion Freight Line(ODFL):這隻紅利成長股值得你關注
- 是否有一個合理的價格購買縫紉機修理股票?
- 3個20美元以下的SmidCaps將回升
- 隨着電動汽車市場競爭日益激烈,繼續評估特斯拉的未來
Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《安提貝治療日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對安替比治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。